Company Overview
Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy. The company also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
Why Investors Should Care
Revenue has grown at a 13.2% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $26.55M (-51.0% YoY); net profit $-91.72M.
- Trailing 12 Months Year-on-year growth — revenue -77.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 13.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 13.21% |
| 1 Year: | -77.40% |
Stock Price Performance
| 1 Year: | -56.74% |
| 6 Months: | +23.20% |
| 3 Months: | +89.66% |
| 1 Month: | +119.69% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)59.93 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 13.2% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 62.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CELU Celularity Inc. PHARMA | 1.54 | -0.43 | $44.58M | 0.00% | - | - | 13.21% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 3.35M | 2.66M | 3.20M | 10.62M | 5.93M | 3.78M | 4.13M | 3.94M | 2.94M | 3.79M | 14.68M | 12.11M | 9.30M | 11.43M | 5.74M | 5.28M |
| Gross Profit | - | - | - | - | - | 2.32M | 1.42M | 1.76M | 8.31M | 1.91M | 597.00K | -3.08M | 1.93M | 2.14M | 184.00K | - | - | - | - | - | - |
| Operating Income | -121 | -115.25K | -202.00K | -241.64K | -208.23K | -4.81M | -44.40M | -60.61M | 10.90M | -41.61M | 4.17M | -5.65M | -63.87M | -42.48M | -99.26M | -7.38M | -10.18M | -11.53M | -10.49M | -15.86M | -12.90M |
| Net Income | -121 | 634.66K | 1.12M | 6.37M | -12.11M | -46.33M | -81.54M | -64.48M | 49.94M | -62.87M | 47.83M | 4.80M | -64.02M | -47.95M | -93.88M | -22.01M | -6.49M | -16.10M | -19.75M | -24.52M | -23.08M |
| Diluted EPS | - | - | - | - | - | -2.52 | - | -2.69 | 0.40 | -0.48 | 0.32 | 0.03 | -4.12 | -2.72 | -4.98 | -1.03 | -0.30 | -0.73 | -0.84 | -1.02 | -0.88 |
| R&D Expense | - | - | - | - | - | 11.22M | 16.99M | 22.91M | 23.77M | 21.67M | 25.35M | 20.35M | 16.95M | 8.60M | 5.18M | 5.84M | 3.80M | 3.92M | 3.73M | 3.35M | 4.60M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 14.28M | 21.34M | 17.98M | 22.77M | 54.22M | 26.55M |
| Gross Profit | - | 9.35M | 11.68M | -1.69M | 6.75M | - | - |
| Operating Income | -564.34K | -151.93M | -109.06M | -25.60M | -192.29M | -38.36M | -61.31M |
| Net Income | 2.51M | -208.23M | -100.12M | 14.19M | -196.29M | -57.89M | -91.72M |
| Diluted EPS | - | - | -1.49 | 0.95 | -11.02 | -2.64 | -3.59 |
| R&D Expense | - | 52.71M | 88.35M | 78.36M | 30.46M | 17.39M | 15.03M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | 174.46K | 291.61M | 431.01M | 414.13M | 401.07M | 143.89M | 132.68M | 107.33M |
| Total Equity | 23.90K | -327.42M | -531.40M | 99.42M | 198.90M | 40.96M | 8.84M | -38.06M |
| Cash & Equivalents | 24.71K | 917.01K | 54.31M | 37.24M | 13.97M | 227.00K | 738.00K | 6.17M |
| Total Liabilities | 150.56K | 11.04M | 412.30M | 314.71M | 202.16M | 102.93M | 123.84M | 145.39M |
| Current Liabilities | 150.56K | 229.09K | 26.68M | 26.23M | 62.09M | 67.30M | 53.68M | 80.76M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.10M | -63.19M | -110.10M | -137.88M | -38.69M | -6.40M | -13.25M |
| Investing Cash Flow | -286.85M | -12.81M | -5.90M | -5.24M | -4.05M | 514.00K | - |
| Financing Cash Flow | 288.84M | 102.01M | 98.56M | 119.84M | 24.09M | 6.70M | 18.65M |
| Capital Expenditure | - | -27.83M | -6.20M | -5.24M | -1.05M | -161.00K | - |
| Free Cash Flow | - | -91.03M | -116.30M | -143.11M | -39.73M | -6.56M | - |
| Share Buybacks | - | 256.00K | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | 65.5% | 54.8% | -9.4% | 29.7% | - | - |
| Operating Margin % | - | -1,064.0% | -511.2% | -142.4% | -844.4% | -70.7% | -230.9% |
| Net Margin % | - | -1,458.4% | -469.3% | 79.0% | -862.0% | -106.8% | -345.4% |
| ROE % | -0.8% | 39.2% | -100.7% | 7.1% | -479.2% | -655.1% | 241.0% |
| ROCE % | -0.2% | -37.6% | -28.1% | -7.6% | -251.1% | -48.6% | -230.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | C V STARR & CO INC | 2.64% | 764.07K | $1.00M |
| 2 | Vanguard Capital Management LLC | 2.15% | 621.11K | $813.65K |
| 3 | Geode Capital Management, LLC | 0.58% | 167.15K | $218.97K |
| 4 | Citadel Advisors Llc | 0.34% | 99.05K | $129.76K |
| 5 | Vanguard Fiduciary Trust Co | 0.28% | 79.87K | $104.63K |
| 6 | Blackrock Inc. | 0.26% | 76.36K | $100.03K |
| 7 | State Street Corporation | 0.20% | 57.83K | $75.76K |
| 8 | HRT Financial LP | 0.20% | 56.59K | $74.13K |
| 9 | Northern Trust Corporation | 0.15% | 44.16K | $57.85K |
| 10 | Biltmore Family Office, LLC | 0.12% | 35.00K | $45.85K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CELU
Why Celularity Stock Jumped 126% Today - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTFBLM2hOeFVIMW1RZ2RFNkdzcTFDX3c1NFN0T2xCaXZLZmx2OGhLb0lBdkdkWWprOXpEVVdnUlpxRk5aOTNFdE1sMGhoaUVrdlJWbEZGWFU2amNPdTY4WGZzQTFxOUg3MjZ2VS1uRXp1MTBuWmcyLU4yZ0lXQWVRdw?oc=5" target="_blan…
Why Is Celularity Stock Gaining Thursday? - Benzinga
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQeWpxUXpjMmstWmUzMkN5OFEwSVoxUS13UWl1Q2MxVlkta0RtNFFjS2lRXzFEa2V6MjhzRG0xREhLNHZadjVkT2tMU2JQS2FiblIycXI4UGgzRjU3SlJXbGdzM2liQ051emM1RjQ1djkwN3BUTTVHd0Q4M3ZIMW9XZjdMSk1KNlVGN2xMQ2…
More than 200 jobs are anticipated in Celularity's expanded New Jersey collaboration - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQUWRZcmdwYVk5cHBjYXNxSHlRUkpvcS1ZaElsZHZYZ2dvbFZiSkg2NUpFOEFYX01paFNsNU5JZGRpUUk3SV9iSWNEbERzc1pDUl9xanp3MlN2YU5KOEh1cHVlaFkxMzdzUjFFRGpyTWhyaUVfc2l6amhLRURRRDNHRDlrUmRjQkxIYy0xQ1…
CELU Stock Grinds Higher As Traders Track Volatile Reversal - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE80ZThMZldKSEhYb056a0dGdkxjUUNib1NJMXlkSTVoUV9ZZ2lzd0pjdm5ZWVVWQ3VKb1pSMk5JTUl0QkFLeWtrblQ3bm93TER6dXpuVmcybFhORWtlMTRqZGZIbkJ4NXNodW1McVpScEFGVXJCdmc?oc=5" target="_blank">CELU Sto…
Celularity (CELU) Stock News & Analysis - TechStock²
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE8zcXUtM0RKbHNQYTBRQWlFbE1QWkFDU2xmZ3dZWE52RG92Q2x4cXhEOXNjVTNqelhNMnA5WXFxalBCU2h0ZlRNeTZIZWIzNEpLQ3c?oc=5" target="_blank">Celularity (CELU) Stock News & Analysis</a> <…
CELU - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9mNWJPQ1FJQjE0ZUttQldfUjRIeEJnazZ2QXd5S3QzQzNpdEhYUk0zTUFVRDk3RVlCWUJ3NzB6Wmp6dEdreFE?oc=5" target="_blank">CELU</a> <font color="#6f6f6f">Finviz</font>…
CELU — Frequently Asked Questions
What is the current share price of Celularity Inc. (CELU)?
As of 2026-09-19 21:16 PDT, Celularity Inc. (CELU) trades at $1.54 on NasdaqCM. Its 52-week range is $0.60 to $4.15.
What is the market capitalisation of CELU?
Celularity Inc. (CELU) has a market capitalisation of $44.58M on NasdaqCM.
What is the P/E ratio of CELU?
CELU trades at a trailing price-to-earnings (P/E) ratio of -0.43. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -1.09.
Is CELU a good stock to buy?
This page provides a data-driven analysis of Celularity Inc. (CELU), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.